Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?

Sub-lobar resection as new standard-of-care for cT1aN0 NSCLC?

Presented By
Dr Nasser Altorki, Weill Cornell Medicine, NY, USA
Conference
WCLC 2022
Trial
Phase 3, CALGB 140503
Doi
https://doi.org/10.55788/5ec6017a
In a randomised phase 3 trial, sub-lobar resection (SLR) was non-inferior to lobar resection in patients with peripheral cT1aN0 non-small cell lung cancer (NSCLC) and tumour sizes ≤2 cm. According to the authors, these results establish SLR as the standard-of-care for this subset of patients [1]. “Although lobar resection has been the standard-of-care for patients with cT1N0 NSCLC for a long time, recent evidence showed that SLR may be non-inferior to lobar resection in a subset of patients [2],” explained Dr Nasser Altorki (Weill Cornell Medicine, NY, USA). The current phase 3 CALGB 140503 trial (NCT00499330) randomised 697 patients with peripheral T1aN0 NSCLC, with tumours ≤2 cm and without metastases to major hilar or mediastinal lymph nodes, 1:1 to lobar resection or SLR. Disease-free survival (DFS) was the primary outcome of the trial. After a median fo...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on